)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Avacta Group
Avacta Group (AVCT) investor relations material
Avacta Group H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary30 Sep, 2026
Executive summary
Achieved clinical validation for the pre|CISION® platform, with AVA6103 showing proof of mechanism and favorable safety in Phase 1a trials for solid tumors, outperforming marketed ADCs in preclinical studies.
Advanced AVA6207 dual payload program and AVA6000 (faridoxorubicin), with updated efficacy and pharmacology data presented at major oncology conferences.
Strengthened leadership with new Board appointments and raised approximately £19 million through equity placements and subscriptions to support R&D and operational runway.
Financial highlights
Revenue from continuing operations was £0.06 million for H1 2026, unchanged from H1 2025.
Operating loss from continuing operations decreased to £13.91 million (H1 2025: £14.18 million).
Loss after tax from continuing operations was £19.02 million (H1 2025: £16.13 million).
Cash and cash equivalents at 30 June 2026 were £20.27 million (31 December 2025: £16.86 million), with £10.59 million as of 31 August 2026.
Net assets at 30 June 2026 were £3.77 million (30 June 2025: £0.14 million).
Outlook and guidance
First efficacy data from the FOCUS-01 trial with AVA6103 expected in H1 2027.
Dual payload program (AVA6207) payload selection and clinical candidate data to be presented in Q4 2026.
Updated AVA6000 clinical data to be presented at ESMO Congress in October 2026.
Current cash runway extends into early Q1 2027, with additional capital raise planned.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Avacta Group
- pre|CISION® PDCs deliver potent, tumor-selective therapy with superior safety and efficacy.AVCT
Corporate presentation - Clinical progress, new leadership, and financial strategy were central themes at the AGM.AVCTAGM 2025
- Strong R&D advances and successful fundraising set up key clinical milestones for late 2026.AVCTAGM 2026 presentation
- Advanced oncology pipeline, strong R&D spend, and cash runway into 2027 with key data ahead.AVCTH2 2025
- Tumor-selective drug delivery platform shows strong early efficacy and safety, with major milestones ahead.AVCTCorporate presentation
- Clinical pipeline advances, cash runway extends to Q1 2026, and industry interest grows.AVCTH1 2025
- Diagnostics turned EBITDA positive as AVA6000 advanced and Diagnostics divestment progressed.AVCTH1 2024
- Focused on AVA6000's clinical progress, board evolution, and strategic funding for 2024 milestones.AVCTAGM 2024
- Advanced oncology pipeline, strong clinical data, and cash runway into Q1 2026; more funding needed.AVCTH2 2024
Next Avacta Group earnings date
H2 202630 Apr, 2027
Avacta Group
Next Avacta Group earnings date
H2 202630 Apr, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Avacta Group PLC is a biotechnology company specializing in the development of innovative diagnostic and therapeutic solutions. The company operates in two primary segments: diagnostics, where it develops rapid tests and reagents, and therapeutics, focusing on the development of precision oncology treatments. Avacta utilizes proprietary technologies, such as its Affimer platform, to create targeted therapies and diagnostic tools. The company is headquartered in Wetherby, United Kingdom, and its shares are listed on the AIM.